Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 688.55
(0.19%)
INR 688.55
(0.19%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 773.41 Million INR | -59.97% |
| 2022 | 1.09 Billion INR | 5.58% |
| 2021 | 1.03 Billion INR | 17.6% |
| 2020 | 882.25 Million INR | -7.05% |
| 2019 | 949.13 Million INR | 11.09% |
| 2018 | 854.42 Million INR | 11.62% |
| 2017 | 765.44 Million INR | -4.83% |
| 2016 | 804.29 Million INR | 7.16% |
| 2015 | 750.56 Million INR | 18.48% |
| 2014 | 633.5 Million INR | -11.06% |
| 2013 | 712.31 Million INR | -2.36% |
| 2012 | 729.55 Million INR | -6.33% |
| 2011 | 778.89 Million INR | 18.69% |
| 2010 | 656.25 Million INR | 31.0% |
| 2009 | 500.94 Million INR | 17.0% |
| 2008 | 428.16 Million INR | -9.37% |
| 2007 | 472.44 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 117.33 Million INR | 24.38% |
| 2024 Q2 | 343.87 Million INR | 12.9% |
| 2023 Q1 | 296.2 Million INR | 13.99% |
| 2023 Q2 | 290.1 Million INR | -2.06% |
| 2023 Q3 | 245.09 Million INR | -15.52% |
| 2023 FY | 438.55 Million INR | -59.97% |
| 2023 Q4 | 94.33 Million INR | -61.51% |
| 2022 Q3 | 287 Million INR | 8.07% |
| 2022 Q1 | 274.21 Million INR | 0.18% |
| 2022 FY | 1.09 Billion INR | 5.58% |
| 2022 Q4 | 259.83 Million INR | -9.46% |
| 2022 Q2 | 265.58 Million INR | -3.15% |
| 2021 Q4 | 273.72 Million INR | 0.61% |
| 2021 FY | 1.03 Billion INR | 17.6% |
| 2021 Q3 | 272.05 Million INR | 1.49% |
| 2021 Q2 | 268.06 Million INR | 9.7% |
| 2021 Q1 | 244.37 Million INR | 11.51% |
| 2020 FY | 882.25 Million INR | -7.05% |
| 2020 Q3 | 256.08 Million INR | 7.15% |
| 2020 Q2 | 238.98 Million INR | 42.81% |
| 2020 Q1 | 167.34 Million INR | -17.85% |
| 2020 Q4 | 219.14 Million INR | -14.42% |
| 2019 Q4 | 203.69 Million INR | -20.81% |
| 2019 FY | 949.13 Million INR | 11.09% |
| 2019 Q1 | 247.92 Million INR | 17.03% |
| 2019 Q3 | 257.2 Million INR | 8.62% |
| 2019 Q2 | 236.78 Million INR | -4.49% |
| 2018 Q1 | 200.59 Million INR | -10.93% |
| 2018 Q2 | 222.41 Million INR | 10.88% |
| 2018 Q3 | 219.58 Million INR | -1.27% |
| 2018 Q4 | 211.83 Million INR | -3.53% |
| 2018 FY | 854.42 Million INR | 11.62% |
| 2017 Q1 | 170.31 Million INR | -16.74% |
| 2017 Q4 | 225.19 Million INR | 13.48% |
| 2017 Q3 | 198.45 Million INR | 15.73% |
| 2017 Q2 | 171.47 Million INR | 0.68% |
| 2017 FY | 765.44 Million INR | -4.83% |
| 2016 Q1 | 222.26 Million INR | 6.31% |
| 2016 FY | 804.29 Million INR | 7.16% |
| 2016 Q2 | 216.41 Million INR | -2.63% |
| 2016 Q3 | 166.02 Million INR | -23.29% |
| 2016 Q4 | 204.56 Million INR | 23.22% |
| 2015 FY | 750.56 Million INR | 18.48% |
| 2015 Q4 | 209.07 Million INR | 3.15% |
| 2015 Q3 | 202.69 Million INR | 10.68% |
| 2015 Q2 | 183.14 Million INR | 16.08% |
| 2015 Q1 | 157.77 Million INR | 4.89% |
| 2014 Q3 | 155.81 Million INR | -4.86% |
| 2014 Q2 | 163.77 Million INR | 0.25% |
| 2014 Q1 | 163.36 Million INR | -23.88% |
| 2014 FY | 633.5 Million INR | -11.06% |
| 2014 Q4 | 150.42 Million INR | -3.46% |
| 2013 Q1 | 155.58 Million INR | 0.38% |
| 2013 Q2 | 177.27 Million INR | 13.94% |
| 2013 Q4 | 214.62 Million INR | 30.2% |
| 2013 Q3 | 164.84 Million INR | -7.01% |
| 2013 FY | 712.31 Million INR | -2.36% |
| 2012 Q1 | 184.77 Million INR | -5.59% |
| 2012 Q2 | 189.96 Million INR | 2.81% |
| 2012 Q3 | 199.81 Million INR | 5.18% |
| 2012 Q4 | 154.99 Million INR | -22.43% |
| 2012 FY | 729.55 Million INR | -6.33% |
| 2011 FY | 778.89 Million INR | 18.69% |
| 2011 Q3 | 203.23 Million INR | -0.64% |
| 2011 Q2 | 204.53 Million INR | 0.0% |
| 2011 Q4 | 195.7 Million INR | -3.7% |
| 2010 FY | 656.25 Million INR | 31.0% |
| 2009 FY | 500.94 Million INR | 17.0% |
| 2008 FY | 428.16 Million INR | -9.37% |
| 2007 FY | 472.44 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ajanta Pharma Limited | 30.46 Billion INR | 97.461% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | 29.625% |
| Sigachi Industries Limited | 579.88 Million INR | -33.373% |
| Bal Pharma Limited | 389.89 Million INR | -98.366% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 63.59% |
| Medico Remedies Limited | 161.84 Million INR | -377.874% |
| Lasa Supergenerics Limited | 291.17 Million INR | -165.618% |
| Venus Remedies Limited | 1.91 Billion INR | 59.64% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 74.863% |
| Alpa Laboratories Limited | 156.14 Million INR | -395.309% |
| Nectar Lifesciences Limited | 625.55 Million INR | -23.637% |
| Shilpa Medicare Limited | 2.18 Billion INR | 64.532% |
| Aarti Drugs Limited | 1.16 Billion INR | 33.754% |
| Lupin Limited | 95.67 Billion INR | 99.192% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 98.029% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 98.209% |
| Windlas Biotech Limited | 1 Billion INR | 23.159% |
| Suven Life Sciences Limited | 109.75 Million INR | -604.702% |
| Eris Lifesciences Limited | 4.94 Billion INR | 84.353% |
| Valiant Laboratories Limited | 36.28 Million INR | -2031.252% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 90.811% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 83.112% |
| Ipca Laboratories Limited | 13.91 Billion INR | 94.442% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 45.505% |
| Achyut Healthcare Limited | 1.6 Million INR | -47967.744% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.498% |
| Bajaj HealthCare Limited | 985.34 Million INR | 21.509% |
| RPG Life Sciences Limited | 1.63 Billion INR | 52.711% |
| Mankind Pharma Limited | 23.15 Billion INR | 96.66% |
| Laurus Labs Limited | 3.01 Billion INR | 74.312% |
| Piramal Pharma Limited | 19.91 Billion INR | 96.116% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 17.932% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 96.39% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 95.126% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.855% |
| Unichem Laboratories Limited | 6.72 Billion INR | 88.501% |
| Sequent Scientific Limited | 2.9 Billion INR | 73.347% |
| Novartis India Limited | 470.1 Million INR | -64.52% |
| Wanbury Limited | 1.16 Billion INR | 33.38% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 44.866% |
| Wockhardt Limited | 6.4 Billion INR | 87.915% |
| Themis Medicare Limited | 782.85 Million INR | 1.206% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 94.649% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 93.356% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.193% |
| Divi's Laboratories Limited | 14.17 Billion INR | 94.542% |
| NATCO Pharma Limited | 10.05 Billion INR | 92.31% |
| Gufic Biosciences Limited | 1.07 Billion INR | 28.236% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 29.613% |
| Ind-Swift Limited | 946.56 Million INR | 18.293% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 74.18% |
| FDC Limited | 5.34 Billion INR | 85.54% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -1575.643% |
| Granules India Limited | 7.18 Billion INR | 89.232% |
| Medicamen Biotech Limited | 335.16 Million INR | -130.754% |
| Alkem Laboratories Limited | 32.83 Billion INR | 97.645% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 70.258% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -4671.279% |
| Brooks Laboratories Limited | 51.18 Million INR | -1411.157% |
| Megasoft Limited | 49.52 Million INR | -1461.561% |
| ZIM Laboratories Limited | 1.01 Billion INR | 23.656% |
| Strides Pharma Science Limited | 9.16 Billion INR | 91.559% |
| Neuland Laboratories Limited | 2.92 Billion INR | 73.601% |
| Morepen Laboratories Limited | 1.98 Billion INR | 61.085% |
| Hikal Limited | 2.48 Billion INR | 68.894% |
| Indoco Remedies Limited | 4.74 Billion INR | 83.713% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 74.844% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -87.527% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -14.385% |
| Hester Biosciences Limited | 908.84 Million INR | 14.901% |